and Roche Group subsidiary Genentech have signed a multi-programme research partnership and licence agreement worth approximately $1.42bn to discover, develop and market respiratory and ophthalmology therapies.
According to the deal, Pieris will get $20m in upfront payment from Genentech. Pieris is also eligible to get additional payments of about $1.4bn across multiple programmes on meeting milestones, and tiered royalties for marketed programmes.
As part of the collaboration, Pieris will be in charge of discovering programmes and their early preclinical development. Genentech will handle the investigational new drug-enabling works as well as clinical development and marketing of these products.
Furthermore, Genentech holds an option to select further targets for an additional option exercise charge.
The research partnership will combine Pieris鈥� Anticalin technology with Genentech鈥檚 targets, and preclinical and clinical development capabilities, to develop new treatments for respiratory and ophthalmological indications.
These therapy areas are well-suited to the benefits of the small size of Anticalin proteins when administered locally.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPieris Pharmaceuticals president and CEO Stephen Yoder said: 鈥淭his collaboration further expands our partnered efforts in respiratory diseases and opens a new avenue for our Anticalin technology to potentially provide patient benefit through local biological effects.
鈥淭his is our second respiratory alliance with a major biopharma company and we remain deeply committed to inhaled biologics, which have already shown benefit in the clinic.鈥�
The company noted that the partnership is not inclusive of any of its internal programmes.
In February 2018,聽Pieris signed a collaboration and licence agreement with聽Seattle Genetics聽for the development of a variety of targeted bispecific immuno-oncology therapies to treat solid tumours and blood cancers.
Separately, (BMS) has signed a technology licence agreement with for non-exclusive access to the latter鈥檚 Xtend fragment crystallisable (Fc) technology to prolong the half-life of a new antibody combination therapy, SARS-CoV-2 mAb Duo, for Covid-19.
Xencor鈥檚 technology demonstrated the ability to amplify circulating half-life by boosting binding affinity to the neonatal Fc receptor.
As per the deal, BMS will handle the therapy鈥檚 research, development, regulatory and commercial works while Xencor is eligible to get royalties from net sales of products.
In March last year,聽Xencor entered a technology licence agreement with Vir Biotechnology聽providing the latter with non-exclusive access to Xtend Fc technology.
